Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion submitted an application for a Phase 3 Clinical Trial Plan to the US FDA for CT-P44, a biosimilar referencing Darzalex, targeting patients with refractory or relapsed multiple myeloma.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: Submission of Application for Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) to US FDA
- Regulatory Authority: US Food and Drug Administration (FDA)
- Application Date (Local Time): 2024-11-29
- Confirmation Date: 2024-11-29 (Date IND application submission to FDA was confirmed)
- Clinical Trial Details
- Study Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Clinical Trial to Compare the Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Subjects with Refractory or Relapsed Multiple Myeloma
- Phase: Global Phase 3
- Target Indication: Refractory or Relapsed Multiple Myeloma
- Registration Number: EU CT number 2024-518588-36-00
- Patient Count: 486 subjects
- Duration: 2 years
- Purpose: To demonstrate biosimilarity by comparing efficacy and safety between CT-P44 and Darzalex
- Regulatory Process & Investment Risks
- Celltrion plans to demonstrate biosimilarity through efficacy and safety results compared to the reference drug Darzalex in this Phase 3 trial.
- Statistically, the probability of a clinical-stage drug candidate receiving final authorization is approximately 10%. Commercialization plans may be altered or abandoned based on trial outcomes.
- Content of this disclosure will be utilized in upcoming press releases and IR materials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring US FDA Approval of Phase 3 Clinical Trial Plan
This disclosure serves as official notification that Celltrion submitted an application for a Phase 3 Clinical Trial Plan for CT-P44 to the US FDA. Tracking whether FDA approval for the Phase 3 Clinical Trial Plan is obtained is important for monitoring progress. Relevant updates can be confirmed through subsequent disclosures or official IR materials.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
